2025 American Academy of Neurology Abstract Website

Objective:

The aim of our study was to evaluate the efficacy, tolerability, and impact on disease burden of BoNT-A use in preventing
episodic migraine (EM).

Background:

OnabotulinumtoxinA (BoNT-A) is approved for prophylactic treatment of chronic migraine (CM) only.

Design/Methods:

This is a prospective study included migraine patients, aged 18 -65 years, and completed one year treatment with BoNT-A. Patients received 4 courses of BoNT-A treatment. Patient’s headache was assessed by headache diary at baseline, and before every injection. Migraine Specific Quality of Life Questionnaire (MSQ) and work productivity were collected at baseline and in their last visit. Adverse events (AEs) were reported.

Results:

The study recruited 210 patients. Between baseline and the final visit, there were a significant reduction in migraine days, analgesic consumption days, and headache severity (9.54 +1.70 versus 4.58+ 2.77, P < 0.001), (8.47 +1.49 versus 2.98+ 0.21, P < 0.001), (8.37+ 0.72versus 2.54 +0.18, P < 0.001), respectively. BoNT-A treatment reduced the mean number of missed hours from work and daily activities over a 7-day period (4.63 +2.39 versus 6.26 +2.04, P < 0.001); (2.24+ 3.30 versus 3.94 +3. 45; P < 0.001). Treatment with BoNT-A significantly improved the MSQ scores at last visit versus baseline visit, MSQ Role Function- Restrictive (51.55 +29.12 vs.26.89+ 17.42; P<0.001), MSQ Role Function-Preventive (56.07+ 24.73 vs. 30.64+ 15.25; P<0.001), and for MSQ Emotional Function (76.47 +115.29 vs. 35.12+ 20.83; P<0.001). 54 patients (14.4%) experienced mild, short-lasting AEs.

Conclusions:

BoNT-A is an effective and well tolerated therapy in the prophylaxis of EM, improving MSQ and WPAI.